Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | GAA | P10253 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887303 | 0.86 | MAPT (0.62) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 | |
| SCHEMBL1878569 | 0.85 | MAPT (0.62) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 | |
| SCHEMBL12158054 | 0.83 | MAPT (0.61) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 | |
| SCHEMBL27214009 | 0.82 | CHRNA7 (0.57) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 | |
| SCHEMBL24997144 | 0.81 | CHRNA7 (0.56) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 | |
| SCHEMBL29190354 | 0.81 | CHRNA7 (0.56) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 | |
| SCHEMBL12158063 | 0.79 | PTGDR2 (0.77) | PTGDR2MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL12639832 | 0.78 | ALDH1A1 (0.59) | PTGDR2MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL30712542 | 0.78 | CHRNA7 (0.47) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 | |
| SCHEMBL1884701 | 0.78 | CHRNA7 (0.61) | PTGDR2MAPTGAASMN1; SMN2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | claimed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | PTGDR2 3872/4885MAPT 2506/4885GAA 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.